Page 39 - IMO-2-2

Innovative Medicines & Omics Herbal remedies for diabetes mellitus

and glucokinase: Results from the SEARCH for diabetes in Indian perspective. Adv Ther. 2019;36(3):520-547.
youth. J Clin Endocrinol Metab. 2013;98(10):4055-4062.
doi: 10.1007/s12325-019-0872-8
doi: 10.1210/jc.2013-1279
42. Moreno-Castilla C, Mauricio D, Hernandez M. Role of
30. Anık A, Çatlı G, Abacı A, Böber E. Maturity-onset diabetes medical nutrition therapy in the management of gestational
of the young (MODY): an update. J Pediatr Endocrinol diabetes mellitus. Curr Diab Rep. 2016;16(4):22.
Metab. 2015;28(3-4):251-263.
doi: 10.1007/s11892-016-0717-7
doi: 10.1515/jpem-2014-0384
43. Ley SH, Hamdy O, Mohan V, Hu FB. Prevention and
31. Alam S, Hasan MK, Neaz S, Hussain N, Hossain MF, management of type 2 diabetes: Dietary components and
Rahman T. Diabetes mellitus: Insights from epidemiology, nutritional strategies. Lancet. 2014;383(9933):1999-2007.
biochemistry, risk factors, diagnosis, complications and doi: 10.1016/S0140-6736(14)60613-9
comprehensive management. Diabetology. 2021;2(2):36-50.
44. McCall MD, Toso C, Baetge EE, Shapiro AM. Are stem cells
doi: 10.3390/diabetology2020004
a cure for diabetes? Clin Sci. 2010;118(2):87-97.
32. Stene LC, Norris JM, Rewers MJ. Risk factors for type 1 doi: 10.1042/CS20090072
diabetes. In: Diabetes in America. Bethesda, MD: National
Institute of Diabetes and Digestive and Kidney Diseases 45. Sheik Abdulazeez S. Diabetes treatment: A rapid review of
(NIDDK); 2023. the current and future scope of stem cell research. Saudi
Pharm J. 2015;23(4):333-340.
33. Ismail L, Materwala H, Al Kaabi J. Association of risk factors
with type 2 diabetes: A systematic review. Comput Struct doi: 10.1016/j.jsps.2013.12.012
Biotechnol J. 2021;19:1759-1785. 46. Bonner-Weir S, Baxter LA, Schuppin GT, Smith FE.
doi: 10.1016/j.csbj.2021.03.003 A Second pathway for regeneration of adult exocrine and
endocrine pancreas: A possible recapitulation of embryonic
34. Petry CJ. Gestational diabetes: Risk factors and recent development. Diabetes. 1993;42(12):1715-1720.
advances in its genetics and treatment. Br J Nutr.
2010;104(6):775-787. doi: 10.2337/diab.42.12.1715
doi: 10.1017/S0007114510001741 47. Lorenzati B, Zucco C, Miglietta S, Lamberti F, Bruno G.
Oral hypoglycemic drugs: Pathophysiological basis of
35. Balaji R, Duraisamy RK. Complications of diabetes mellitus: their mechanism of actionoral hypoglycemic drugs:
A review. Drug Invent Today. 2019;12(1):98-103.
Pathophysiological basis of their mechanism of action.
36. DeFronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes Pharmaceuticals. 2010;3(9):3005-3020.
mellitus. Nat Rev Dis Prim. 2015;1(1):15019.
doi: 10.3390/ph3093005
doi: 10.1038/nrdp.2015.19
48. Donnor T, Sarkar S. Insulin-pharmacology, therapeutic
37. Cooper M, Warren AM. A promising outlook for diabetic regimens and principles of intensive insulin therapy. In:
kidney disease. Nat Rev Nephrol. 2019;15(2):68-70. Endotext. South Dartmouth, MA: MDText.com, Inc.; 2000.
doi: 10.1038/s41581-018-0092-5 49. Thota S, Akbar A. Insulin. In: StatPearls [Internet]. Treasure
Island (FL): StatPearls Publishing; 2025.
38. Lovisa S, LeBleu VS, Tampe B, et al. Epithelial-to-
mesenchymal transition induces cell cycle arrest 50. Inzucchi S, Rosenstock J, Umpierrez GE. Type 2 Diabetes
and parenchymal damage in renal fibrosis. Nat Med. and insulin secretagogues. J Clin Endocrinol Metab.
2015;21(9):998-1009. 2012;97(3):37A-37A.
doi: 10.1038/nm.3902 doi: 10.1210/jcem.97.3.zeg37a
39. Kato M, Natarajan R. Epigenetics and epigenomics in 51. Garber AJ. Long-acting glucagon-like peptide 1 receptor
diabetic kidney disease and metabolic memory. Nat Rev agonists. Diabetes Care. 2011;34(Supplement_2):S279-S284.
Nephrol. 2019;15(6):327-345.
doi: 10.2337/dc11-s231
doi: 10.1038/s41581-019-0135-6
52. Filippatos TD, Panagiotopoulou T V., Elisaf MS. Adverse
40. Bahadoran Z, Mirmiran P, Azizi F. Dietary polyphenols effects of GLP-1 receptor agonists. Rev Diabet Stud.
as potential nutraceuticals in management of diabetes: 2014;11(3-4):202-230.
A review. J diabetes Metab Disord. 2013;12(1):43.
doi: 10.1900/RDS.2014.11.202
doi: 10.1186/2251-6581-12-4.
53. Kalra S, Bhutani J. Alpha-glucosidase inhibitors. In:
41. Viswanathan V, Krishnan D, Kalra S, et al. Insights on Diabetology: Type 2 Diabetes Mellitus. India: Jaypee Brothers
medical nutrition therapy for type 2 diabetes mellitus: An Medical Publishers Pvt Ltd.; 2014. p. 55-55.

Volume 2 Issue 2 (2025) 33 doi: 10.36922/imo.7520